This is a pilot, randomized, open-labelled study. Eligible patients will be enrolled and
randomized 1:1 into "anticoagulation" arm or "anticoagulation plus atorvastatin" arm, with
atorvastatin given at 40 mg orally daily for 3 months. The targeted total accrual is 80
patients, with 40 in each arm. Patients will be recruited from the hospitals and clinics at
The Ohio State University Wexner Medical Center. Follow up visits are planned at enrollment,
3 months, and 9 months after randomization. At each follow up, blood will be obtained and
assessments will include structured interviews of signs and symptoms of recurrent venous
thromboembolism (VTE), bleeding, post thrombotic syndrome, and adverse events from study
drugs.